Article
Analysis of BRAF and NRAS Mutation Status in Advanced Melanoma Patients Treated with Anti-CTLA-4 Antibodies: Association with Overall Survival?
PloS one - 1 Jan 2015
Mangana Joanna, Cheng Phil F, Schindler Katja, Weide Benjamin, Held Ulrike, Frauchiger Anna L, Romano Emanuella, Kähler Katharina C, Rozati Sima, Rechsteiner Markus, Moch Holger, Michielin Olivier, Garbe Claus, Hauschild Axel, Hoeller Christoph, Dummer Reinhard, Goldinger Simone M
Abstract excerpt
Ipilimumab and tremelimumab are human monoclonal antibodies (Abs) against cytotoxic T-lymphocyte antigen-4 (CTLA-4). Ipilimumab was the first agent to show a statistically significant benefit in overall survival in advanced melanoma patients. Currently, there is no proven association between the BRAFV600 mutation and the disease control rate in response to ipilimumab. This analysis was carried out to assess if...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.